EGFR and lung adenocarcinoma: To analyse the prognostic factors of survival for patients harbouring activating mutations who received EGFR-TKIs, multiple factors including age, gender, smoking status, PS score, histological type, disease type, activating mutation type, and lines of treatments were enrolled for univariate and multivariate analysis, and the results showed that there was a significant difference in survival between patients with lung adenocarcinoma and patients with lung squamous cell carcinoma (24.5 months vs. 7.3 months, Hazard Ratio 11.984, 95% CI 3.873 to 37.082, p < 0.001).